Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialarticle Published on 2023-10-042024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] JAK1/2 inhibitors JAKoMo clinical trial myelofibrosis Patient-reported outcome measures (PROMs) Real-world evidence ruxolitinib [DOI] 10.1007/s00277-023-05458-1 PMC 바로가기 [Article Type] article